Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -3.87%84 Net Margin % is 11.88% as of Dec. 2025, which is 1% below its 10-year median of 11.96. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 960 Drug Manufacturers companies, Synmosa Biopharma ranks better than 74.17% on this metric.
The historical rank and industry rank for Synmosa Biopharma's Net Margin % or its related term are showing as below:
ROCO:4114'
s Net Margin % Range Over the Past 10 Years
Min: 0.25 Med: 11.96 Max: 21
Current: 13.28
ROCO:4114's Net Margin % is ranked better than 74.17% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs ROCO:4114: 13.28
Synmosa Biopharma (ROCO:4114) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Synmosa Biopharma Net Margin % Related Terms
Synmosa Biopharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma (ROCO:4114) has a Net Margin % of 11.88% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Synmosa Biopharma and its competitors. This is near median its historical median of 11.96. Over the past decade, Synmosa Biopharma's Net Margin % has ranged from 0.25 to 21.00. According to the industry distribution chart, Synmosa Biopharma ranks #248 out of 960 companies in the Drug Manufacturers industry, placing it in the top 25.8%.
Is Synmosa Biopharma's Net Margin % too high?
Synmosa Biopharma's current Net Margin % of 11.88% is near median its 10-year median of 11.96. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 21.00. The Drug Manufacturers industry median Net Margin % is 5.64. Synmosa Biopharma's value of 11.88% is 110.8% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #248 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #248 out of 960 companies for Net Margin %. This puts Synmosa Biopharma in the upper half of its industry. The industry median Net Margin % is 5.64. Synmosa Biopharma's value of 11.88% is 110.8% above this benchmark. Historically, Synmosa Biopharma's own Net Margin % has ranged from 0.25 to 21.00 over the past decade. While the company's 10-year median is 11.96 vs. the industry median of 5.64, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Net Margin % of 11.88% is 110.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Net Margin % is 11.88%, which is near median its own 10-year median of 11.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.93, compared to a current price of NT$29.60 — trading 12.8% below its estimated fair value. The current Net Margin % is 11.88%, which is near median its 10-year median of 11.96 and 110.8% above the Drug Manufacturers industry median of 5.64. Synmosa Biopharma's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Net Margin % is 11.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.60 is trading 12.8% below its estimated GF Value™ of NT$33.93.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Net Margin %: 11.88% (near median its 10-year median of 11.96)
GF Value™: NT$33.93 vs. price of NT$29.60 (12.8% below fair value)
Industry Position: 110.8% above the Drug Manufacturers median (#248 of 960)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
